$-1.48 EPS Expected for Esperion Therapeutics (ESPR); Churchill Downs (CHDN)’s Sentiment Is 1.13

Analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report $-1.48 EPS on May, 3.They anticipate $0.83 EPS change or 127.69% from last quarter’s $-0.65 EPS. After having $-1.29 EPS previously, Esperion Therapeutics Inc’s analysts see 14.73% EPS growth. The stock decreased 2.48% or $0.92 during the last trading session, reaching $36.13. About shares traded. Esperion Therapeutics Inc (NASDAQ:ESPR) has risen 167.43% since September 20, 2016 and is uptrending. It has outperformed by 155.86% the S&P500.

Churchill Downs Incorporated is a racing, gaming and online entertainment company. The company has market cap of $2.82 billion. The Firm is engaged in brick-and-mortar casino gaming with approximately 9,030 gaming positions in seven states, and is a legal mobile and online platform for betting on horseracing in the United States. It has a 26.63 P/E ratio. It operates through six divisions: Racing, Casinos, TwinSpires, Big Fish Games, Other Investments and Corporate.

Esperion Therapeutics, Inc. is a lipid management company. The company has market cap of $804.31 million. The Firm is a late-stage pharmaceutical firm focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . It currently has negative earnings. With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Investors sentiment decreased to 0.88 in Q4 2016. Its down 0.28, from 1.16 in 2016Q3. It worsened, as 15 investors sold Esperion Therapeutics Inc shares while 27 reduced holdings. 12 funds opened positions while 25 raised stakes. 14.57 million shares or 2.54% more from 14.20 million shares in 2016Q3 were reported. Credit Suisse Ag accumulated 695,384 shares. Royal Comml Bank Of Canada holds 0% or 7,376 shares in its portfolio. Next Fincl Grp Incorporated Inc has 92 shares for 0% of their portfolio. Tower Capital Lc (Trc) has invested 0% in Esperion Therapeutics Inc (NASDAQ:ESPR). Millennium Mngmt Ltd Liability Corp invested in 10,195 shares or 0% of the stock. Rhumbline Advisers holds 16,334 shares or 0% of its portfolio. United Svcs Automobile Association accumulated 0% or 35,280 shares. Geode Management Ltd Com holds 0% or 129,084 shares. Martingale Asset Management Limited Partnership accumulated 50,711 shares or 0.01% of the stock. Gilder Gagnon Howe & Lc has 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR). Virginia Retirement Systems Et Al owns 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR) for 22,600 shares. Commercial Bank Of America Corporation De holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 110,523 shares. Pentwater Capital Mngmt Limited Partnership has 0.29% invested in Esperion Therapeutics Inc (NASDAQ:ESPR). Tekla Cap Mngmt Ltd Llc, Massachusetts-based fund reported 102,800 shares. Morgan Stanley has 80,086 shares.

Among 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. Esperion Therapeutics had 35 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) has “Equal-Weight” rating given on Wednesday, June 29 by Barclays Capital. The stock has “Sell” rating by Chardan Capital Markets on Friday, August 7. RBC Capital Markets maintained it with “Sector Perform” rating and $30 target in Thursday, February 23 report. The company was maintained on Tuesday, December 15 by RBC Capital Markets. As per Tuesday, February 28, the company rating was upgraded by Citigroup. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Buy” rating by Citigroup on Wednesday, June 29. Lake Street initiated the shares of ESPR in report on Monday, October 26 with “Buy” rating. As per Monday, August 10, the company rating was upgraded by Needham. The firm has “Underperform” rating by Credit Suisse given on Wednesday, June 29. Citigroup downgraded the stock to “Neutral” rating in Monday, November 14 report.

The stock increased 1.56% or $2.65 during the last trading session, reaching $172. About shares traded. Churchill Downs, Inc. (NASDAQ:CHDN) has risen 15.71% since September 20, 2016 and is uptrending. It has outperformed by 4.13% the S&P500.

Since January 1, 0001, it had 0 buys, and 16 insider sales for $53.61 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.